BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: S. aureus monofunctional glycosyltransferase

...structural studies to guide compound optimization. TARGET/MARKER/PATHWAY: S. aureus monofunctional glycosyltransferase LICENSING STATUS: Patented by Alchemia Ltd....
...Zuegg, J. et al. Nat. Commun.; published online July 21, 2015 doi:10.1038/ncomms8719 CONTACT: Wim Meutermans, Alchemia Ltd....
BioCentury | Aug 10, 2015
Company News

Alchemia, Panther Biotechnology deal

...Panther will acquire Alchemia’s Alchemia Oncology Pty Ltd. subsidiary in a deal slated to close by...
...a Phase II trial as second-line treatment of mCRC. The companies could not be reached. Alchemia Ltd....
BioCentury | Nov 17, 2014
Company News

Alchemia management update

Alchemia Ltd. (ASX:ACL), Brisbane, Australia Business: Chemistry, Cancer, Hematology Departed: Thomas Liquard as CEO WIR Staff cancer Hematology...
BioCentury | Nov 3, 2014
Clinical News

HA-Irinotecan: Phase III data

...of OS showed that both treatment arms led to an OS of about 14 months. Alchemia...
...and said it will report further on its review and corporate strategy in early 2015. Alchemia...
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Merck KGaA (Xetra:MRK, Darmstadt, Germany) market Erbitux. Alchemia Ltd....
BioCentury | Sep 1, 2014
Company News

Mesoblast management update

...Novartis AG’s Australia and New Zealand group; he succeeds Jenni Pilcher, who became CFO of Alchemia Ltd. WIR...
BioCentury | Sep 1, 2014
Company News

Imugene management update

...Ltd. (ASX:IMU), Armadale, Australia Business: Drug delivery Hired: Charles Walker as CEO, formerly CEO of Alchemia Ltd. WIR...
BioCentury | Sep 1, 2014
Company News

Alchemia management update

Alchemia Ltd. (ASX:ACL), Brisbane, Australia Business: Chemistry, Cancer, Hematology Hired: Jenni Pilcher as CFO, formerly secretary and CFO of Mesoblast Ltd. WIR Staff cancer Hematology...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...Inc. (TSX: AEZ; NASDAQ:AEZS) Macimorelin acetate (AEZS-130) Diagnose adult growth hormone deficiency PDUFA date 11/5/14 Alchemia Ltd....
BioCentury | Jun 30, 2014
Clinical News

HA-Irinotecan: Phase II started

...in about 50 patients with mCRC. HA-Irinotecan is in Phase III testing to treat mCRC. Alchemia...
...Merck markets the drug elsewhere, except in Japan where the 3 companies market the drug. Alchemia Ltd....
BioCentury | Jun 23, 2014
Clinical News

HA-Irinotecan: Phase III ongoing

...of PFS, which resulted in fewer events by June 30 than the company originally planned. Alchemia...
...statistical power of the FDA-requested substudy (see BioCentury, Feb. 11, 2013 & March 4, 2013). Alchemia...
Items per page:
1 - 10 of 72
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: S. aureus monofunctional glycosyltransferase

...structural studies to guide compound optimization. TARGET/MARKER/PATHWAY: S. aureus monofunctional glycosyltransferase LICENSING STATUS: Patented by Alchemia Ltd....
...Zuegg, J. et al. Nat. Commun.; published online July 21, 2015 doi:10.1038/ncomms8719 CONTACT: Wim Meutermans, Alchemia Ltd....
BioCentury | Aug 10, 2015
Company News

Alchemia, Panther Biotechnology deal

...Panther will acquire Alchemia’s Alchemia Oncology Pty Ltd. subsidiary in a deal slated to close by...
...a Phase II trial as second-line treatment of mCRC. The companies could not be reached. Alchemia Ltd....
BioCentury | Nov 17, 2014
Company News

Alchemia management update

Alchemia Ltd. (ASX:ACL), Brisbane, Australia Business: Chemistry, Cancer, Hematology Departed: Thomas Liquard as CEO WIR Staff cancer Hematology...
BioCentury | Nov 3, 2014
Clinical News

HA-Irinotecan: Phase III data

...of OS showed that both treatment arms led to an OS of about 14 months. Alchemia...
...and said it will report further on its review and corporate strategy in early 2015. Alchemia...
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Merck KGaA (Xetra:MRK, Darmstadt, Germany) market Erbitux. Alchemia Ltd....
BioCentury | Sep 1, 2014
Company News

Mesoblast management update

...Novartis AG’s Australia and New Zealand group; he succeeds Jenni Pilcher, who became CFO of Alchemia Ltd. WIR...
BioCentury | Sep 1, 2014
Company News

Imugene management update

...Ltd. (ASX:IMU), Armadale, Australia Business: Drug delivery Hired: Charles Walker as CEO, formerly CEO of Alchemia Ltd. WIR...
BioCentury | Sep 1, 2014
Company News

Alchemia management update

Alchemia Ltd. (ASX:ACL), Brisbane, Australia Business: Chemistry, Cancer, Hematology Hired: Jenni Pilcher as CFO, formerly secretary and CFO of Mesoblast Ltd. WIR Staff cancer Hematology...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...Inc. (TSX: AEZ; NASDAQ:AEZS) Macimorelin acetate (AEZS-130) Diagnose adult growth hormone deficiency PDUFA date 11/5/14 Alchemia Ltd....
BioCentury | Jun 30, 2014
Clinical News

HA-Irinotecan: Phase II started

...in about 50 patients with mCRC. HA-Irinotecan is in Phase III testing to treat mCRC. Alchemia...
...Merck markets the drug elsewhere, except in Japan where the 3 companies market the drug. Alchemia Ltd....
BioCentury | Jun 23, 2014
Clinical News

HA-Irinotecan: Phase III ongoing

...of PFS, which resulted in fewer events by June 30 than the company originally planned. Alchemia...
...statistical power of the FDA-requested substudy (see BioCentury, Feb. 11, 2013 & March 4, 2013). Alchemia...
Items per page:
1 - 10 of 72